January 2025 in “Advances in Clinical Medicine” Fractional CO2 laser therapy effectively improves skin conditions and recovery when combined with other treatments.
March 2024 in “Cytologia” LncRNA MTC boosts growth of goat skin cells, improving cashmere quality.
52 citations
,
September 2022 in “Viruses” SARS-CoV-2 proteins help the virus avoid the immune system, delaying response and increasing inflammation.
14 citations
,
April 2019 in “International Journal of Women's Health” Some treatments can stabilize Frontal Fibrosing Alopecia, but more research is needed to find effective treatments, and hair transplants often fail.
2 citations
,
July 2023 in “Animals” FGF10 and non-coding RNAs are important for cashmere goat hair follicle development.
January 2017 in “Springer eBooks” The document concludes that Cutaneous Lupus Erythematosus has different forms, is influenced by genetic and environmental factors, and can be treated with various medications, but more targeted therapies are needed.
65 citations
,
May 2006 in “Journal of Investigative Dermatology” Dexamethasone may influence hair growth by altering estrogen receptor activity in hair cells.
April 2026 in “Cosmetics” The formulation significantly increased hair density and thickness safely in people with androgenetic alopecia.
21 citations
,
November 2015 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” There is no cure for alopecia areata, but treatments like JAK inhibitors show promise.
2 citations
,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
1 citations
,
March 2023 in “Clinical, Cosmetic and Investigational Dermatology” Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
March 2025 in “Journal of Education Health and Sport” Alopecia areata causes hair loss due to immune issues, and while new treatments show promise, no universally effective solution exists yet.
September 2023 in “Drugs in context” Baricitinib is a promising treatment for alopecia areata.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
2 citations
,
May 2025 in “Journal of Clinical Medicine” Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
May 2025 in “Skin Appendage Disorders” Frontal fibrosing alopecia can be diagnosed by examining facial areas and treated with specific medications to stop its progression.
1 citations
,
January 2023 in “SAGE open medical case reports” A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
March 2022 in “Wound practice & research” New treatments for alopecia areata show promise, but standardized guidelines are needed.
August 2023 in “JAAD international” Pediatric dermatologists have varied preferences for treating alopecia areata in children, with no standard FDA-approved treatments and some using JAK inhibitors despite risks.
2 citations
,
May 2023 in “International Journal of Molecular Sciences” The TRPV3 ion channel is important for skin and hair health and could be a target for treating skin conditions.
November 2025 in “Biomedicines” JAK1 inhibitors can help reduce itchiness in atopic dermatitis.
50 citations
,
April 2010 in “Biology direct” Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.
18 citations
,
January 2021 in “Theranostics” The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
August 2023 in “Dermatology and Therapy” Experts recommend personalized treatment plans for best outcomes in managing Alopecia Areata.
3 citations
,
February 2019 in “Der Urologe” Medications for benign prostatic syndrome can cause cognitive issues and depression.
September 2025 in “PubMed” Prevent persistent hair loss after chemotherapy with scalp cooling and early minoxidil use.